Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
Published: April 01, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer's PFE stock has been trading steadily above its 50-day and 200-day simple moving averages (SMAs) since early January, signaling sustained investor confidence. The stock is also up about 12.8% so far in 2026.
Read More
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Published: April 01, 2026 by: Reuters
Sentiment: Negative
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.
Read More
Pfizer: Why Wall Street Habitually Overestimates Target Price
Published: March 27, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer Inc. (PFE) currently receives a buy rating from Wall Street, but I believe the rating is overoptimistic. Political uncertainties around 'TrumpRx' and 'Most-Favored-Nation' drug pricing models continue to threaten PFE's margins and valuation outlook. PFE's FWD P/E of 9.3x appears attractive on the surface, but is actually not once the multi-year earnings decline risks are factored in.
Read More
Why Pfizer Remains A Strong Buy In 2026
Published: March 27, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer started 2026 on a high note despite ongoing skepticism from retail investors. Its key anti-cancer drugs, Padcev, Lorbrena, and Talzenna, showed strong performance in Q4. Accordingly, sales of Talzenna rose 81.5% year-on-year to $49 million.
Read More
This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In
Published: March 25, 2026 by: 24/7 Wall Street
Sentiment: Positive
It's rare to get such a massive high-yielder that's also positioning itself for long-term growth.
Read More
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade
Published: March 25, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer is reiterated as a Buy, reflecting undervaluation and strong long-term potential despite near-term patent cliffs and macroeconomic uncertainty. PFE's robust drug pipeline, aggressive acquisitions, and strategic focus on obesity and oncology attempt to offset $17–18B in annual revenue at risk from LOEs. Dividend sustainability is questioned, with payout exceeding 100% of FCF based on 2025 data, and a possible cut is supported to preserve balance sheet strength amid rising debt.
Read More
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial
Published: March 24, 2026 by: 24/7 Wall Street
Sentiment: Positive
Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year.
Read More
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive
Published: March 23, 2026 by: WSJ
Sentiment: Positive
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
Read More
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Published: March 23, 2026 by: CNBC
Sentiment: Neutral
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the results, but cited "strong efficacy" for its decision to move forward.
Read More
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer Use
Published: March 20, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer's Talzenna/Xtandi combo meets phase III goals, significantly delaying disease progression in HRR-mutated metastatic castration-sensitive prostate cancer patients.
Read More
TrumpRx lists many medicines at prices higher than paid in UK
Published: March 18, 2026 by: Reuters
Sentiment: Negative
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those paid in the United Kingdom, according to a Reuters comparison of publicly available prices.
Read More
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
Published: March 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer (PFE) Down 0.6% Since Last Earnings Report: Can It Rebound?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Negative
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Read More
Can Pfizer Reignite Growth Amid COVID Declines and Patent Expirations?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE faces falling COVID sales, looming patent cliffs and IRA pressure. It is betting on cost cuts, new launches and pipeline rebuilds to revive growth.
Read More
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Published: March 04, 2026 by: The Motley Fool
Sentiment: Positive
Teva Pharmaceutical is a bit of a turnaround story, as the company continues a major business overhaul. This competitor, with a huge 6.3% yield, has hit a few setbacks, but it is still just business as usual.
Read More
Seven S&P500 Ideal 'Safer' March Dividend Dogs
Published: March 04, 2026 by: Seeking Alpha
Sentiment: Positive
Seven S&P 500 dividend 'Dogs'—including VICI, VZ, BEN, F, HST, T, and KEY—offer high yields supported by sufficient free cash flow, making them attractive buys. Analyst forecasts project 14.2% to 32.2% net gains for the top ten S&P 500 dividend stocks by March 2027, with an average estimated gain of 20.51%. Dividend safety is emphasized: only stocks with positive free cash flow margins and yields from $1K invested exceeding share prices are considered 'safer' and ideal for purchase.
Read More
Pfizer's Portfolio Renewal In Progress - High Yields For The Patient
Published: March 04, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer's portfolio renewal is in progress, with new launches and acquisitions driving +14.6% YoY growth in new product revenues, though legacy drug expiries may pressure intermediate-term sales. These developments lend credence to their frenzied M&A/licensing activities despite the potential debt risks, given the reasonable, estimated net interest coverage ratio of 6.91x. Their R&D efforts are still reasonable at ~16.6% of their top lines in FY2025, near their 5Y pre-pandemic averages of ~16.3%, with it presenting the sector's capital-intensive R&D/M&A thesis.
Read More
Pfizer's Quiet Cash Comeback
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer delivers a 75.81% gross margin and 41.05% EBITDA margin, dramatically outperforming sector medians of 59.35% and 10.40%. Management targets $1.3 billion in net cost savings by 2026, reinforcing structural margin durability despite revenue pressure. Trailing operating cash flow reached $13.08 billion, fully covering $9.8 billion in dividends with a 6.22% yield.
Read More
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's PFE stock has risen 11% so far in 2026. The stock has also been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since early January.
Read More
Pfizer CEO flags issues with FDA's vaccine leadership
Published: March 02, 2026 by: Reuters
Sentiment: Negative
Pfizer CEO Albert Bourla on Monday flagged issues with the leadership of the U.S. Food and Drug Administration's vaccine department.
Read More
PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative.
Read More
My 5 Favorite Dividend Stocks to Buy Right Now
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.
Read More
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Read More
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Read More
Top High-Yield Stocks to Double Up on Right Now
Published: February 19, 2026 by: The Motley Fool
Sentiment: Positive
Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.
Read More
Is There 25% Downside For Pfizer Stock?
Published: February 18, 2026 by: Forbes
Sentiment: Negative
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.
Read More
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Positive
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
Read More
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Published: February 10, 2026 by: Reuters
Sentiment: Neutral
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000